DrugPatentWatch Database Preview
Teva Womens Company Profile
» See Plans and Pricing
What is the competitive landscape for TEVA WOMENS, and when can generic versions of TEVA WOMENS drugs launch?
TEVA WOMENS has eight approved drugs.
There are three US patents protecting TEVA WOMENS drugs.
There are twenty-four patent family members on TEVA WOMENS drugs in sixteen countries and nineteen supplementary protection certificates in thirteen countries.
Summary for Teva Womens
| International Patents: | 24 |
| US Patents: | 3 |
| Tradenames: | 14 |
| Ingredients: | 8 |
| NDAs: | 8 |
Drugs and US Patents for Teva Womens
Expired US Patents for Teva Womens
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Womens | ZEBETA | bisoprolol fumarate | TABLET;ORAL | 019982-002 | Jul 31, 1992 | 4,258,062*PED | Start Trial |
| Teva Womens | PREFEST | estradiol; norgestimate | TABLET;ORAL | 021040-001 | Oct 22, 1999 | 6,747,019 | Start Trial |
| Teva Womens | ADDERALL 10 | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | TABLET;ORAL | 011522-007 | Feb 13, 1996 | 6,384,020*PED | Start Trial |
| Teva Womens | ADDERALL 7.5 | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | TABLET;ORAL | 011522-011 | Aug 31, 2000 | 6,384,020*PED | Start Trial |
| Teva Womens | ZEBETA | bisoprolol fumarate | TABLET;ORAL | 019982-001 | Jul 31, 1992 | 4,258,062*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA WOMENS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 20 mg, 30 mg | ➤ Subscribe | 2009-11-18 |
International Patents for Teva Womens Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 029159 | Start Trial |
| World Intellectual Property Organization (WIPO) | 0059577 | Start Trial |
| Australia | 3412300 | Start Trial |
| World Intellectual Property Organization (WIPO) | 0105407 | Start Trial |
| European Patent Office | 1202739 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Womens Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2316456 | 132017000142109 | Italy | Start Trial | PRODUCT NAME: NALTREXONE/BUPROPIONE(MYSIMBA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/988, 20150330 |
| 1453521 | 300814 | Netherlands | Start Trial | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| 1453521 | 39/2015 | Austria | Start Trial | PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| 1453521 | 93156 | Luxembourg | Start Trial | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| 1214076 | C01214076/01 | Switzerland | Start Trial | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
